Innovative Microbiome Therapies MaaT Pharma specializes in microbiome-driven immunotherapies for oncology and hemato-oncology, presenting opportunities for collaboration with biotech firms and healthcare providers focusing on cancer treatment advancements.

Strong Funding & Expansion With recent €37.5 million loan from the European Investment Bank and $44 million in funding, MaaT Pharma is positioned for accelerated clinical development and commercialization, presenting potential for investment and partnership opportunities.

Strategic Collaborations Partnerships with global pharmaceutical services like Clinigen highlight MaaT Pharma's focus on scaling therapies such as Xervyteg, opening avenues for distribution, licensing, and co-marketing collaborations across European markets.

Regulatory & Clinical Progress Positive clinical trial outcomes and active participation in major hematology and oncology conferences indicate a mature pipeline ready for commercialization, offering opportunities for healthcare providers and investors interested in cutting-edge cancer therapies.

Market Position & Growth Listed on Euronext Paris since 2021 with a focused team of up to 200 employees, MaaT Pharma’s niche in microbiome immunotherapy positions it as a compelling partner for companies seeking innovative treatments or technology licensing in the biotech space.